Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regeneron Pharmaceuticals (NQ: REGN ) 1,069.74 +6.14 (+0.58%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 299,561 Open 1,075.35 Bid (Size) 1,031.00 (1) Ask (Size) 1,083.00 (1) Prev. Close 1,063.60 Today's Range 1,064.95 - 1,078.70 52wk Range 721.51 - 1,106.16 Shares Outstanding 91,779,465 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News $100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today Today 15:00 EDT Via Benzinga Peering Into Regeneron Pharmaceuticals's Recent Short Interest July 19, 2024 Via Benzinga Performance YTD +18.20% +18.20% 1 Month +0.55% +0.55% 3 Month +18.84% +18.84% 6 Month +13.46% +13.46% 1 Year +47.12% +47.12% More News Read More Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst July 18, 2024 Via Benzinga 3 Standout Stocks to Buy for the Next Bull Market July 18, 2024 Via InvestorPlace Stocks to Buy: 7 Founder-Led Companies Set to Outperform July 17, 2024 Via InvestorPlace Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology July 16, 2024 Via Benzinga The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals July 11, 2024 Via Benzinga If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today July 04, 2024 Via Benzinga CPI Data Sparks Rally in Biotech Stocks July 15, 2024 Via MarketBeat Topics ETFs Economy Exposures Interest Rates Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling July 15, 2024 Via Benzinga Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split July 15, 2024 Via The Motley Fool The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 July 09, 2024 Via InvestorPlace Looking Into Regeneron Pharmaceuticals's Recent Short Interest July 02, 2024 Via Benzinga Healthcare Stocks Continue To Lag The Market-Can Anything Help ? July 08, 2024 Via Talk Markets 3 No-Brainer Stocks to Buy in July July 08, 2024 Via The Motley Fool 3 Pharma Stocks Already Ushering in the Next Biotech Boom July 08, 2024 Via InvestorPlace The 3 Best Biotech Stocks to Buy in July 2024 July 05, 2024 Via InvestorPlace What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients July 05, 2024 Via Investor's Business Daily 7 High Priced Stocks That Would Benefit From a Stock Split July 04, 2024 Via InvestorPlace Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data July 03, 2024 Via Benzinga Exposures Product Safety Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD July 03, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire What's Going On With Regeneron Pharmaceuticals Stock On Friday? June 28, 2024 Via Benzinga Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma June 28, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 June 27, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product June 27, 2024 Via Benzinga Exposures Product Safety Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.